Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.